Cutaneous T-cell Lymphoma (CTCL) – Market Insights, Epidemiology and Market Forecast 2027- Market In

Albany, Feb 13, 2019 (Issuewire.com) – Cutaneous T-cell Lymphoma (CTCL) – Market Insights, Epidemiology and Market Forecast 2027– Market Insights, Epidemiology and Market Forecast-2027

Men account for over 53% of the total cases of CTCL as compared to women.

More on StockNewDesk:

  • Cutaneous T-cell lymphomas (CTCL) are the most common types of skin lymphoma.
  • More than 3 out of every 4 skin lymphomas diagnosed are CTCLs. They often appear as eczema-like skin rashes and can affect widespread parts of the body.
  • There are different subtypes of CTCL. Most are slow growing but some can be fast growing. The most common types of CTCL are Mycosis Fungoides and Sezary Syndrome.

(Albany, US) DelveInsight launched a new report on Cutaneous T-cell Lymphoma (CTCL) – Market Insights, Epidemiology and Market Forecast-2027

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Cutaneous T-cell lymphoma (CTCL) market.
  • Organize sales and marketing efforts by identifying the best opportunities for Cutaneous T-cell lymphoma (CTCL) market.
  • To understand the future market competition in the Cutaneous T-cell lymphoma (CTCL) market.

Request for sample pages

Market study carried out for the period of 2016-2027 shows that the Market Size of Cutaneous T-cell Lymphoma was about USD 698.47 Billion in 2016 in the 7MM, growing at an increasing CAGR during the forecasted period (2018-2027).

More on StockNewDesk:

As per DelveInsight estimates, men account for over 53% of total cases of CTCL, as compared to women. The total incident population of CTCL in the 7 major markets was approximately 8400 cases in 2016. DelveInsight estimates higher incident cases of CTCL in the United States with approximately 3,200 incident cases in 2016, followed by EU5 and Japan and also, there are approximately 1,700 cases of Mycosis fungoides in 2016 in the US. The incidence rate of Mycosis fungoides has been increasing significantly since the 1970s.

The treatment of CTCL depends on the disease stage. Early stage therapies are topical, including corticosteroids, retinoids, imiquimod (Aldara), ultraviolet A irradiation (PUVA), and total skin electron beam therapy. Systemic therapies are introduced in the advanced stages where the disease is widespread and/or resistant to topical treatment. These include interferon alpha injections, stem cell transplant, alemtuzumab (MabCampath) and other chemotherapy regimens. The United States had the highest market share of Cutaneous T-cell Lymphoma (CTCL) in 2016, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. The market size for the Early Stage First Line & Second Line Therapies of CTCL in the United States was found to be approx. USD 28.22 Million and USD 265.3 Million respectively in 2016.

Cutaneous T-cell Lymphoma Drug Companies

  • Medivir AB
  • 4SC AG
  • Soligenix

And many others

Drugs covered

  • SGX301
  • Remetinostat

And many others

Table of contents

1. Report Introduction

2. Cutaneous T- Cell Lymphoma Market Overview at a Glance

2.1. Total Market Share Distribution of Cutaneous T- Cell Lymphoma for 7 MM in 2017

2.2. Total Market Share Distribution of Cutaneous T- Cell Lymphoma for 7 MM in 2027

  • Cutaneous T- Cell Lymphoma Overview

3.1. Introduction

3.2. Types

3.3. Causes

3.4. Pathophysiology

3.5. Symptoms

3.6. Diagnosis

  • Epidemiology of Cutaneous T-Cell Lymphoma

4.1. United States

4.1.1. Assumptions and Rationale

4.1.2. Incident Population of Cutaneous T-Cell Lymphoma

4.1.3. Treatable Cases of Cutaneous T-Cell Lymphoma in the United States

4.1.4. Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the United States

4.1.5. Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the United States

4.1.6. Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in the United States

4.1.7. Early Stage-Specific Incidence of CTCL in the United States

4.1.8. Late Stage-Specific Incidence of CTCL in the United States

4.2. Europe

4.3. Assumptions and Rationale

4.3.1. Germany

4.3.1.1. Incident Population of Cutaneous T-Cell Lymphoma in Germany

4.3.1.2. Treatable Cases of Cutaneous T-Cell Lymphoma in Germany

4.3.1.3. Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany

4.3.1.4. Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany

4.3.1.5. Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany

4.3.1.6. Early Stage-Specific Incidence of CTCL in Germany

4.3.1.7. Late Stage-Specific Incidence of CTCL in Germany

4.3.2. France

4.3.2.1. Incident Population of Cutaneous T-Cell Lymphoma in France

4.3.2.2. Treatable Cases of Cutaneous T-Cell Lymphoma in the France

4.3.2.3. Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France

4.3.2.4. Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France

4.3.2.5. Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France

4.3.2.6. Early Stage-Specific Incidence of CTCL in France

4.3.2.7. Late Stage-Specific Incidence of CTCL in France

4.3.3. Italy

4.3.3.1. Incident Population of Cutaneous T-Cell Lymphoma in Italy

4.3.3.2. Treatable Cases of Cutaneous T-Cell Lymphoma in Italy

4.3.3.3. Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy

4.3.3.4. Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy

4.3.3.5. Stage-Specific Incidence of utaneous T-Cell Lymphoma in Italy

4.3.3.6. Early Stage-Specific Incidence of CTCL in Italy

4.3.3.7. Late Stage-Specific Incidence of CTCL in Italy

4.3.4. Spain

4.3.4.1. Incident Population of Cutaneous T-Cell Lymphoma in Spain

4.3.4.2. Treatable Cases of Cutaneous T-Cell Lymphoma in Spain

4.3.4.3. Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain

4.3.4.4. Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain

4.3.4.5. Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain

4.3.4.6. Early Stage-Specific Incidence of CTCL in Spain

4.3.4.7. Late Stage-Specific Incidence of CTCL in Spain

4.3.5. United Kingdom

4.3.5.1. Incident Population of Cutaneous T-Cell Lymphoma in the UK

4.3.5.2. Treatable Cases of Cutaneous T-Cell Lymphoma in the United Kingdom

4.3.5.3. Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in the United Kingdom

4.3.5.4. Gender Specific Incidence of Cutaneous T-Cell Lymphoma in the United Kingdom

4.3.5.5. Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in the UK

4.3.5.6. Early Stage-Specific Incidence of CTCL in the UK

4.3.5.7. Late Stage-Specific Incidence of CTCL in the UK

4.4. Japan

4.4.1. Incident Population of Cutaneous T-Cell Lymphoma in Japan

4.4.2. Treatable Cases of Cutaneous T-Cell Lymphoma in Japan

4.4.3. Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan

4.4.4. Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan

4.4.5. Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan

4.4.6. Early Stage-Specific Incidence of CTCL in Japan

4.4.7. Late Stage-Specific Incidence of CTCL in Japan

  • Treatment Algorithm

5.1. International Lymphoma Radiation Oncology Group Guidelines for Modern Radiation Therapy for Primary Cutaneous Lymphomas

5.2. United States

5.3. NCCN Guidelines

5.4. Europe

5.5. ESMO Guidelines

5.6. Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group Guidelines

5.7. EORTC recommendations for the treatment of mycosis fungoides/Se´zary syndrome

  • Unmet Needs
  • Marketed Drugs

7.1. Istodax (Romidepsin): Celgene Corporation

7.1.1. Drug Description

7.1.2. Mechanism of Action

7.1.3. Advantages & Disadvantages

7.1.4. Safety and Efficacy

7.1.5. Product Profile

7.2. Poteligeo (Mogamulizumab): Kyowa Hakko Kirin Co, Ltd.

7.2.1. Drug Description

7.2.2. Mechanism of Action

7.2.3. Advantages & Disadvantages

7.2.4. Safety and Efficacy

7.2.5. Product Profile

7.3. Valchlor/ Ledaga (Mechlorethamine): Actelion

7.3.1. Drug Description

7.3.2. Mechanism of Action

7.3.3. Advantages & Disadvantages

7.3.4. Safety and Efficacy

7.3.5. Product Profile

7.4. Uvadex (Methoxsalen): Mallinckrodt Pharmaceuticals

7.4.1. Drug Description

7.4.2. Mechanism of Action

7.4.3. Advantages & Disadvantages

7.4.4. Safety and Efficacy

7.4.5. Product Profile

7.5. Targretin (Bexarotene): Eisai Co., Ltd.

7.5.1. Drug Description

7.5.2. Mechanism of Action

7.5.3. Advantages & Disadvantages

7.5.4. Safety and Efficacy of Targretin

7.5.5. Product Profile

7.6. Zolinza (Vorinostat): Merck Sharp & Dohme Corp.

7.6.1. Drug Description

7.6.2. Mechanism of Action

7.6.3. Advantages & Disadvantages

7.6.4. Safety and Efficacy of Zolinza

7.6.5. Product Profile

  • Emerging Drugs

8.1. Phase-III Drugs Analysis Monoclonal Antibodies and Photodynamic Therapy

8.2. Phase-II Drugs Analysis – Histone Deacetylase (HDAC) Inhibitors

  • Emerging Therapies

9.1. Brentuximab Vedotin: Seattle Genetics

9.1.1. Product Description

9.1.2. Research and Development

9.1.3. Product Development Activities

9.1.4. Product Profile

9.2. SGX301: Soligenix

9.2.1. Product Description

9.2.2. Research and Development

9.2.3. Product Development Activities

9.2.4. Product Profile

9.3. Quisinostat: Janssen

9.3.1. Product Description

9.3.2. Research and Development

9.3.3. Product Development Activities

9.3.4. Product Profile

9.4. Resminostat: 4SC AG

9.4.1. Product Description

9.4.2. Research and Development

9.4.3. Product Development Activities

9.4.4. Product Profile

9.5. Remetinostat: Medivir AB

9.5.1. Product Description

9.5.2. Research and Development

9.5.3. Product Development Activities

9.5.4. Product Profile

  • Cutaneous T- Cell Lymphoma: Country-Wise Market Analysis

10.1. Total Market Size of Early Stage Cutaneous T- Cell Lymphoma for 7 MM in 2017-2027

10.2. Total Market Size of Late Stage Cutaneous T- Cell Lymphoma for 7 MM in 2017-2027

10.3. Total Market Size of Cutaneous T- Cell Lymphoma for 7 MM in 2017-2027

10.4. Assumptions and Caveats (7MM)

10.5. United States

10.5.1. Market Outlook

10.5.2. Stage-Specific Market Size of CTCL in the United States

10.5.3. Market Size of CTCL in the United States

10.6. Europe

10.6.1. Market Outlook

10.6.2. Germany

10.6.2.1. Stage-Specific Market Size of CTCL in Germany

10.6.2.2. Market Size of CTCL in Germany

10.6.3. France

10.6.3.1. Stage-Specific Market Size of CTCL in France

10.6.3.2. Market Size of CTCL in France

10.6.4. Italy

10.6.4.1. Stage-Specific Market Size of CTCL in Italy

10.6.4.2. Market Size of CTCL in Italy

10.6.5. Spain

10.6.5.1. Stage-Specific Market Size of CTCL in Spain

10.6.5.2. Market Size of CTCL in Spain

10.6.6. United Kingdom

10.6.6.1. Stage-Specific Market Size of CTCL in the United Kingdom

10.6.6.2. Market Size of CTCL in the United Kingdom

10.7. Japan

10.7.1. Market Outlook

10.7.2. Stage-Specific Market Size of CTCL in Japan

10.7.3. Market Size of CTCL in Japan

  • Market Drivers
  • Market Restraints
  • Appendix
  • Report Methodology

14.1. Sources Used

  • DelveInsight Capabilities
  • Disclaimer

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:

Shruti Thakur

[email protected]

+919650213330

Media Contact

Delveinsight Business Reserarch LLP

[email protected]

9193216187

304 S. Jones Blvd #2432, Las Vegas NV 89107

https://www.delveinsight.com/

Source :DelveInsight

This article was originally published by IssueWire. Read the original article here.

Latest on StockNewDesk:

Login

Lost your password?